AACR Conference Coverage
Featured Articles
(Forbes) Apr 12, 2017 - It's possible that tumor mutation burden (TMB) predicts if cancer―of any type―will respond to treatment with immune drugs, but this remains to be tested.
Read Article
(Forbes) Apr 7, 2017 - Among 112 women with metastatic breast cancer, 11 experienced durable responses to Atezolizumab. The problem is, there’s no way to know in advance who those will be.
Read Article
Latest Articles
November 15, 2017
October 27, 2017
October 27, 2017
October 27, 2017
October 27, 2017
October 27, 2017
October 27, 2017
October 27, 2017
View More
News Commentary
Editor Image
07 Apr, 2017 | by Winston Wong, PharmD
A commendable increase of 28 months of survival ... and the overall cost is? ...
View Comment
View More
Featured Videos
There are no videos.
OBR Blog
Carlo Croce, MD, FAACR, is the recipient of the 2017 AACR Margaret Foti Award for Leadership and Extraordinary... Read more
April 24, 2017
Immunotherapy pioneer Carl June, MD, was named member of the 2017 class of fellows of the American Association for... Read more
April 18, 2017